The Economic Rationality of Preventive Medicine: Social Design in the Era of 48 Trillion Yen Healthcare Costs
Structural analysis of the cost-effectiveness of preventive medicine investment. Comparing healthcare expenditure breakdown and preventive ROI.
What Is Happening
In fiscal year 2023, Japan's national healthcare costs reached 48.0915 trillion yen, a 3.0% increase from the previous year—another record high. Per capita, this translates to 386,700 yen annually, or approximately 27.55 million yen in lifetime medical expenses.
However, examining the ratio between spending "to treat illness" and spending "to prevent illness" within this 48 trillion yen reveals a structural distortion.
Health return per ¥1 spent: Prevention vs Treatment
Preventive Investment
Treatment Cost Structure
99.5% of spending goes to treatment, 0.5% to prevention. The 'prevention paradox': funds concentrate where ROI is lower.
The national budget for prevention-related initiatives is approximately 250 billion yen—merely 0.5% of total healthcare costs. The remaining 99.5% is devoted to treating diseases that have already manifested. While this is not unique to Japan, can this allocation be considered rational given multiple evidence sources showing that the ROI of preventive investment far exceeds that of treatment?
According to Ministry of Health, Labour and Welfare estimates, specific health checkups and health guidance provide returns of 3.0-6.0 yen per yen invested. CDC estimates show influenza vaccination ROI at approximately 6.5 times. WHO analysis indicates smoking cessation programs yield 2.0-3.5 times returns. While figures vary across studies, the finding that prevention is more cost-effective than treatment is nearly consistent.
Yet why doesn't investment flow to prevention? This reveals a structural problem.
Background and Context
The Prevention Paradox: The Destiny of Invisible Effectiveness
The primary reason preventive medicine struggles to attract investment is that "success is invisible." Treatment yields clear results—surgery succeeds and patients recover. Conversely, when prevention succeeds, nothing happens. When people don't get sick, it's impossible to distinguish whether they avoided illness thanks to prevention or would not have gotten sick anyway.
The "prevention paradox" formulated by epidemiologist Geoffrey Rose in 1981 refers to this structure. Even preventive measures that bring great benefits to the entire population appear to offer small benefits at the individual level. Even if a smoking cessation campaign prevents 10,000 premature deaths, none of the 10,000 people saved realize they are on the "saved side."
This paradox directly affects resource allocation in democratic societies. If voters demand budgets for "visible" treatment while remaining indifferent to "invisible" prevention, politicians will allocate budgets to treatment. Rational individual choices collectively create irrational resource allocation—a fundamental challenge in social design that also applies to population decline and Tokyo's excessive concentration.
Healthcare Cost Breakdown: Where Is the Money Going?
Let's examine the 48 trillion yen breakdown in more detail. Inpatient medical costs account for 17.6 trillion yen (36.6%), outpatient medical costs 16.2 trillion yen (33.7%), and pharmacy dispensing costs 8.1 trillion yen (16.9%). The remainder covers dental care, home nursing, and other services.
By disease category, the largest expenditure is circulatory diseases (heart disease, stroke, etc.) at approximately 6 trillion yen, followed by neoplasms (cancer) at about 5 trillion yen, and musculoskeletal diseases (back pain, arthritis, etc.) at around 2.5 trillion yen. All are disease groups closely related to lifestyle habits.
Notable is the relationship with age structure. Per capita medical costs for those 65 and older are approximately 750,000 yen, compared to about 200,000 yen for those under 65—a 3.7-fold difference. As long as the elderly population continues to grow, healthcare cost increases are structurally unavoidable. Government estimates suggest national healthcare costs will reach 68 trillion yen by 2040—a figure that incorporates not only aging progression but also unit cost increases due to advanced medical technology.
International Preventive Investment: What's Different?
According to OECD's "Health at a Glance 2025," Japan's prevention and public health spending is 0.17% of GDP, below the OECD average of 0.23%. In contrast, Finland spends 0.38%, Canada 0.35%, and South Korea 0.31%.
Finland's "North Karelia Project" is known as a successful example of preventive investment. The cardiovascular disease prevention program launched in 1972 centered on dietary guidance and smoking cessation promotion, reducing cardiovascular disease mortality by 80% over 30 years. The economic effects from healthcare cost reduction and labor productivity improvement are estimated to be tens of times the program investment amount.
Japan also has success stories. Nagano Prefecture has worked on salt reduction campaigns and health screening promotion since the 1960s, improving from having the worst stroke mortality rate nationally to currently ranking among the top prefectures for life expectancy. However, such initiatives depend on individual local government efforts and are not incorporated as national systems.
Reading the Structure
Why Do Systems Bias Toward "Treatment"? Three Structural Factors
At least three structural factors underlie the lack of progress in preventive investment.
First, temporal misalignment. Preventive investment effects emerge over 10-30 year spans, but policy cycles (elections, budget compilation) last 1-4 years. Decision-makers have changed by the time effects appear. The institutional design is unsuited for long-term investment.
Second, asymmetric interests. Treatment is tied to massive industries—hospitals, pharmaceuticals, medical devices. Prevention lacks equivalent stakeholders. While health food and fitness industries exist, their lobbying power cannot compare to medical industries.
Third, evidence difficulties. Rigorous measurement of preventive effects requires large-scale, long-term randomized controlled trials. Ethical constraints make this less straightforward than measuring treatment effects. Insufficient evidence leads to lack of investment, and lack of investment prevents evidence accumulation—creating a vicious cycle.
Prevention as Social Design: What Should Change?
As long as preventive medicine is viewed as a matter of "individual health management," the structure won't change. What's needed is repositioning prevention as social infrastructure.
Specifically, three directions are conceivable.
Allocation shift. Redirecting just 1% of healthcare costs—approximately 480 billion yen—to prevention would double the current preventive budget. Whether this is viewed as a "cost" or "investment" fundamentally changes the discussion framework.
Incentive redesign. The current medical system is based primarily on fee-for-service payment linked to "quantity treated." If prevention succeeds and patients stop coming, income decreases. Institutional design is needed that links compensation to improved health outcomes through Pay for Performance (P4P) systems.
Data infrastructure construction. If specific health checkup data, receipt data, and long-term care data could be analyzed comprehensively, the accuracy of measuring preventive investment effects would improve dramatically. However, currently these data are fragmented by ministry and insurer, making cross-sectional analysis difficult.
The 48 trillion yen figure indicates Japan's healthcare system is approaching its limits. Maintaining the current treatment-centered system would expand costs to 68 trillion yen by 2040. The shift to prevention is not idealism but fiscal necessity.
Related Columns
References
令和5年度 国民医療費の概況
厚生労働省. 厚生労働省
Read source
Health at a Glance 2025
OECD. OECD
Read source
特定健康診査・特定保健指導の医療費適正化効果等の検証のためのワーキンググループ
厚生労働省 保険局. 厚生労働省
Read source
The North Karelia Project: A 30-year perspective
Puska, P.. European Heart Journal
Read source